Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter to Distribute BioPorto Acute Kidney Injury Tests

NEW YORK – Danish kidney testing firm BioPorto announced Tuesday that it has entered into an agreement with Danaher subsidiary Beckman Coulter Diagnostics to distribute BioPorto's acute kidney injury (AKI) tests.

Under the agreement, Beckman Coulter will globally distribute BioPorto's neutrophil gelatinase-associated lipocalin (NGAL) tests for use on Beckman's portfolio of DxC and AU clinical chemistry analyzers. Beckman Coulter will initially distribute the NGAL test in Europe, then will distribute in the US pending US Food and Drug Administration marketing clearance for the ProNephro AKI (NGAL) test for use on Beckman Coulter's analyzers, BioPorto said in a statement. ProNephro AKI received FDA clearance for use on Roche's Cobas C 501 analyzer in 2023. The agreement allows for expansion into other geographic areas.

"By expanding our distribution network, enhancing the portfolio of instruments capable of running our tests, and securing collaborations with leading global manufacturers, we are well positioned to accelerate the adoption of our AKI assessment tests," BioPorto Group CEO Peter Mørch Eriksen said in a statement. "This partnership with Beckman Coulter underscores the compelling value of our technology and our commitment to improving patient outcomes."

BioPorto's tests are based on the NGAL biomarker and are intended to help with the risk assessment and diagnosis of AKI.